Results 111 to 120 of about 2,475,393 (270)
The Potential Role of Cyclopeptides from Pseudostellaria heterophylla, Linum usitatissimum and Drymaria diandra, and Peptides Derived from Heterophyllin B as Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes: An In Silico Study. [PDF]
Liao HJ, Tzen JTC.
europepmc +1 more source
ABSTRACT Aims/Introduction Oxidative stress is thought to play a role in the onset and progression of diabetic nephropathy (DN). Nuclear factor erythroid‐related factor 2 (Nrf2) is a master regulator of antioxidant and detoxification pathways and provides cellular protection against oxidative stress.
Suratsawadee Promsuwan +5 more
wiley +1 more source
ABSTRACT Background Obesity's global rise has outpaced the effectiveness of “one‐size‐fits‐all” prevention and treatment strategies. The promise of precision medicine lies in addressing the etiological and biological diversity of obesity and transforming it into actionable endotypes.
Nadia Abu Samra +13 more
wiley +1 more source
Drug‐Induced Sialolithiasis—A Big‐Data Retrospective Study
ABSTRACT Background Sialolithiasis pathophysiology is multifactorial, with systemic medications often hypothesised as a key contributor, particularly in older adults (Drug‐Induced Sialolithiasis). However, robust evidence supporting this theory is limited.
Gal Avishai +5 more
wiley +1 more source
In the realm of clinical management, Papillary Thyroid Cancer (PTC) stands out as a prevalent thyroid malignancy, characterized by significant metabolic challenges, particularly in the context of carbohydrate metabolism.
Angelika Buczyńska +4 more
doaj +1 more source
The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from to
Dipeptidyl peptidase IV (DPP-4), an incretin glucagon-like peptide-1 (GLP-1) degrading enzyme, contains two forms and it can exert various physiological functions particular in controlling blood glucose through the action of GLP-1.
Shian-Ren Lin +6 more
doaj +1 more source
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christian LerchCochrane Metabolic and Endocrine Disorders Group, Department of General Practice, Heinrich-Heine University Duesseldorf, Duesseldorf, GermanyBackground: In type 2 diabetes ...
Elizabeth Bandeira-Echtler +3 more
core
Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor-associated angioedema
Angioedema is a potentially life-threatening adverse effect of angiotensin-converting enzyme inhibitors. Bradykinin and substance P, substrates of angiotensin-converting enzyme, increase vascular permeability and cause tissue edema in animals.
Harris, S +10 more
core +1 more source
[[abstract]]A series of (2S)-cyanopyrrolidines with glutamic acid derivatives at the P2 site have been prepared and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV).
Tsai, TY;Hsu, T;Chen, CT;Cheng, JH;Chiou, MC;Huang, CH;Tseng, YJ;Yeh, TK;Huang, CY;Yeh, KC;Huang, YW;Wu, SH;Wang, MH;Chen, X;Chao, YS;Jiaang, WT
core +1 more source

